ADB-PINACA isomer 1 Stats & Data

• Identification/labels: “Spice/K2” products and vendor labels (including “isomer 1”) are unreliable; contents and dose per gram vary widely, so treat any sample as highly potent until analytically verified. Uneven spraying onto herb can create ‘hot spots’ that deliver multi-milligram boluses and precipitate overdose.

• Dose titration: For inhalation, start <1 mg and wait at least 10–15 minutes before any redose; for oral, wait ≥90 minutes. Avoid stacking doses due to delayed peaks and risk of panic, vomiting, or syncope. General harm-reduction guidance favors conservative titration with new SCRAs.

• Mixing/solvents: If applying to plant material, dissolve a measured amount in volatile solvent (e.g., ethanol/acetone), apply evenly, tumble/mix thoroughly, and fully dry to minimize hot spots. Never sprinkle dry crystals. Community and harm-reduction groups consistently warn about dosing variability in SCRA smoking blends.

• Toxicity profile: Outbreaks linked to ADB-PINACA involved severe agitation, confusion, hypertension and ICU admissions, highlighting a narrow safety margin even in small inhaled doses.

• Class risk context: EMCDDA/EUDA reports for closely related SCRAs (e.g., 5F‑MDMB‑PINACA; MDMB‑4en‑PINACA) document very high CB1 potency and numerous severe poisonings and fatalities at low milligram doses; ADB‑PINACA belongs to the same indazole‑3‑carboxamide class and should be approached with identical caution.

• Set/setting & sitter: Rapid-onset dysphoria, paranoia, and ‘white‑out’ episodes are widely reported; use with a trusted sober sitter and a quiet environment to reduce panic‑driven redosing or hazardous behavior. Harm‑reduction communities emphasize sober supervision for potent SCRAs.

• Contraindications: Avoid if you have a history of seizures, serious cardiovascular disease, or psychosis; SCRA events frequently include seizures, tachyarrhythmias, and severe agitation.

• Polydrug use: Combining with depressants (alcohol, opioids, benzos) increases aspiration and sedation risks if vomiting or syncope occur; combining with stimulants increases cardiac load and panic. Consult interaction charts before mixing.

• Legal/testing: Many jurisdictions control ADB‑PINACA and analogs. Commercial immunoassays often miss specific SCRAs; only targeted LC‑MS/MS detects metabolites reliably—assume low detectability and short parent half‑life but unpredictable detection windows by lab panel. (General lab screening literature on SCRAs; variability is high.)

• Driving/operating machinery: Wait at least 8 hours after last dose and until fully baseline; residual cognitive effects can persist into the next day in some users.